Continucare Corp. yesterday reported its first quarter fiscal year 2010 financial results. The company reported a 113% increase in net income and continued strength in the business with higher quarter-ending cash and working capital balances.

Richard C. Pfenniger, Jr., Continucare’s Chairman and Chief Executive Officer commented, “We are extremely pleased with our first quarter results,” “Record revenues, improved utilization outcomes and operating efficiencies resulted in a 113% increase in net income. Also, during the quarter we added an important new dimension to our business with the launch of Seredor Corporation and the acquisition of our first sleep diagnostic centers.”

First Quarter Highlights Include:

Revenues increased 17% compared to $65.1 million for the same period last year, with total revenue of $76.0 million Income from operations increased 116% to $8.6 million, compared to $4.0 million for the same period last year Launch of Seredor Corporation, a new sleep diagnostic center subsidiary to

Puramed Bioscience Inc. is currently trading at $1.50 per share, up $0.50 or 50%, on volume of about 50,000 shares. The stock, which hit a high of $1.99 earlier today, was mentioned about six months ago – April 2, 2009 – to be exact in the FREE Daily Newsletter from QualityStocks. At the time, Puramed Bioscience’s stock was trading for only 8 cents a share! For investors who jumped aboard at that time, they have seen their holding multiply by nearly 19 times!

Puramed Bioscience engages in the research, development and marketing of non-prescription products. The company’s leading product is LipiGesic M, which provides acute relief from migraine headaches. In addition, Puramed also has plans to launch LipiGesic PM, which provides a remedy for insomnia and other sleep disorders as well as LipiGesic H for common tension headaches.

If you are an investor interested in micro-cap and small-cap stocks, such as Puramed

Somaxon Pharmaceuticals, Inc.

(Public, NASDAQ:SOMX)

StocksHaven Investments profiles one of the most promising biomedical pharmaceutical company involved with a PDUFA with regards to a drug which could quite possibly revolutionize the treatment for insomnia, a condition affecting over 70 million Americans. The company has been making waves the past few months as investors and institutions gain confidence from the highly positive clinical trials, and the recent exclusive meeting with the FDA with regards to their NDA. Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The lead product candidate is Silenor® (doxepin) for the treatment of insomnia. The FDA decision date on Silenor has been set to 12/4/09 for their NDA resubmission, the

Dear Value Seeker,

Yesterday, the “Big Three” automakers came to Washington with a plan: ask for even more money.

GM wants $18 billion, with $4 billion for December’s bills.

Chrysler says it needs $7 billion in the next few months.

Ford is after $9 billion…but only as a precaution. It feels pretty confident it can make it without help.

After all, Ford’s sales fell only 31% year-over-year in November. GM and Chrysler both saw sales for the same period tumble by over 40%.

In exchange for $34 billion in taxpayer money, the automakers promised major restructuring, reduced labor costs (that’s right, it’s promising to fire employees in return for taxpayer backing) and the sale of some product lines.

The CEOs even said they would even work for $1. (Never mind that their salaries only make up about 10% of their overall pay packages.)

But decades of waste and mismanagement aren’t forgotten

Laura Cadden says Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is on the verge of a big breakthrough with a drug to treat sleep disorders. She says investors that buy the stock at or below 75 cents will be in line for double-digit gains.

This from Today’s Financial News:

Maryland-based Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has high hopes for its drug VEC-162. This treatment mimics the action of melatonin — the hormone that that regulates the body’s internal clock.

Vanda is testing the effectiveness of VEC-162 to treat sleep disorders.

Over 60 million adults in the U.S. alone suffering from some form of insomnia. Yet only about 15% seek treatment. Some fear side effects like grogginess and dry mouth.

Others are afraid of becoming reliant on a sleep aid. In fact, many such treatments, including Lunesta and Ambien, are

Hello Friends!  Thanks so much for stopping by and visiting my blog, Stock Picks Bob’s Advice!  As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website.

Earlier today, while looking through the list of top % gainers on the NASDAQ, I came across a stock I would like to briefly share with you, Natus (BABY), which closed at $21.02, up $1.35 or 6.86% on the day.  I do not have any shares nor do I have any options on this stock.  In fact, as the trading day finished up, Natus was no longer on the top % gainers list, but did close with a nice gain, and I think deserves a spot on …